In a new report, analysts at Leerink previewed the upcoming American Society of Clinical Oncology (ASCO) Conference. Analysts broke down what investors need to watch for from the companies presenting at the event.
Affimed NV AFMD 3.9% (Outperform)
Analysts see the preclinical presentation on the combination of AFM13 and CD137 co-stimulation and PD-1 blocking as the “most interesting” topic from the company.
Array BioPharma Inc ARRY 0.83% (Outperform)
Analysts are watching for updates on multiple binimetinib (MEK162) combinations.
Cerulean Pharma Inc CERU 3.51% (Outperform)
Analysts are looking for final data from the Phase 1b/2a trial of CRLX101 with avastin for treatment of renal cell carcinoma.
Dicerna Pharmaceuticals Inc DRNA 6.59% (Outperform)
Analysts would view early disclosure of clinical data from DCR-MYC as a positive.
Exelixis Inc EXEL 0.64% (Market Perform)
Analysts will be watching for several potential updates on cabozantinib and cobimetinib.
ImmunoGen Inc IMGN 2.91% (Market Perform)
Analysts believe investors will mostly be looking for results from the Roche MARIANNE study, but feel that data on IMGN853 could also be coming.
Incyte Corp INCY 0.12% (Outperform)
Analysts are most eager to see data from two Phase I trials of INCB040093 and INCB039110 in B cell malignancies and Hodgkin Lymphoma.
Karyopharm Therapeutics Inc KPTI 1.18% (Outperform)
Analysts believe that potential Phase 2 data from solid tumor studies could serve as a near-term catalyst for the stock.
MacroGenetics Inc MGNX 0.42% (Outperform)
Analysts will be watching Phase I data on margetuximab monotherapy in HER2-positive solid tumors.
Mirati Therapeutics Inc MRTX 0.57% (Outperform)
Analysts want to see at least a 50 percent response rate in the first 10-15 patients of the Phase I study of MGCD265 in patients with advanced solid tumors.
Xencor Inc XNCR 0.82% (Outperform)
Analysts see XmAb7195 and XmAb5871 as the two main drivers for the company, but believe that MOR208 could provide a nice pipeline complement to the two proprietary antibodies.
Read this article and all my other articles for free on Benzinga by clicking here
Want to learn more about the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!
